Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program
April 16 2020 - 7:00AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a
clinical-stage biopharmaceutical company seeking to discover and
develop innovative medicines in areas of significant unmet medical
need, today announced a new drug development program called
COVID-19 HOPE. The program uses a novel combination of two drugs
that have been previously approved by the FDA for other diseases.
The goal of the COVID-19 HOPE program is to develop a therapy to
improve lung function and reduce the amount of time that COVID-19
patients are on ventilators.
“The rapidly increasing number of COVID-19 patients needing
mechanical ventilation is deeply worrisome, as more than one-third
of these patients will never recover lung function and will die on
the ventilator,” stated Dr. Steven Quay, President and CEO of
Atossa Therapeutics. “The problem is confounded by the fact that
hospitals may soon be facing a ventilator shortage and a vaccine
could take more than a year to develop. The two drugs we intend to
combine, which we call AT-H201, have been approved by the FDA for
other diseases and are supported by a dozen clinical studies in
close to 800 patients. We plan to quickly initiate and complete
clinical studies so that we can obtain FDA approval to bring this
treatment to market as soon as possible.”
Atossa has filed comprehensive provisional patent applications
related to AT-H201 and intends to apply to the FDA under its
Coronavirus Treatment Acceleration Program for approval to commence
a clinical study.
About Atossa’s COVID-19 HOPE Program
The program is called “COVID-19 HOPE,” which is an acronym for
AT-H201in COVID-19 patients for
Pulmonary Evaluation. The
intended primary function of the drug combination AT-H201 is to
essentially mimic the function of the antibodies formed from a
vaccine by blocking the ability of the virus to enter the target
cells; a vaccine that may not be available for more than a
year. There are five known key steps the coronavirus must take
to signal the cell to open up and let the virus in. AT-H201 is
being designed to function like a “chemical vaccine” by blocking
all five of those steps, similar to what antibodies would be
expected to do when a vaccine is administered. With AT-H201,
the virus should be unable to enter the cell because its "keys"
that would otherwise open the door into the cell surface, are
disabled. Atossa expects that its AT-H201 drug combination can be
developed more quickly than a traditional vaccine.
About the Inventor, Dr. Steven Quay
AT-H201 was invented by Dr. Steven Quay. Dr. Quay received his
M.D., M.A. and Ph.D. from The University of Michigan, was a
postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a
resident at the Harvard-Massachusetts General Hospital, and was on
the faculty of Stanford University School of Medicine for almost a
decade. He has over 300 published contributions to medicine which
have been cited over 9,700 times. Dr. Quay has founded six
pharmaceutical companies, invented seven FDA-approved medicines,
and holds 87 U.S. patents.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company seeking to discover and develop innovative medicines in
areas of significant unmet medical need. Atossa’s current focus is
on breast cancer and COVID-19. For more information, please visit
www.atossatherapeutics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
preliminary and final clinical results, actions and inactions by
the FDA, the outcome or timing of regulatory approvals needed by
Atossa including those needed to commence studies, lower than
anticipated rate of patient enrollment, estimated market size of
drugs under development, the safety and efficacy of Atossa's
products and services, performance of clinical research
organizations and investigators, obstacles resulting from
proprietary rights held by others, such as patent rights, potential
market sizes for Atossa's drugs under development and other risks
detailed from time to time in Atossa's filings with the Securities
and Exchange Commission, including without limitation its periodic
reports on Form10-K and 10-Q, each as amended and supplemented from
time to time.
Company Contact: Atossa Therapeutics, Inc. Kyle
Guse, CFO and General Counsel Office: 866-893-4927
kyle.guse@atossainc.com
Investor Relations Contact: Scott Gordon Core
IR 377 Oak Street Concourse 2 Garden City, NY 11530
Office:516-222-2560 scottg@corprominence.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2024 to May 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From May 2023 to May 2024